Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor

SIMPLE SUMMARY: In this study, we apply the ERBB2-chimeric antigen receptor (CAR)-modified natural killer (NK) cell line NK-92 (NK-92/5.28.z), a well-defined, good manufacturing practice (GMP)-compliant, third-party, off-the-shelf immune effector cell product as a novel immunotherapeutic approach fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gossel, Leonie D. H., Heim, Catrin, Pfeffermann, Lisa-Marie, Moser, Laura M., Bönig, Halvard B., Klingebiel, Thomas E., Bader, Peter, Wels, Winfried S., Merker, Michael, Rettinger, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004684/
https://www.ncbi.nlm.nih.gov/pubmed/33809981
http://dx.doi.org/10.3390/cancers13061443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004684/
https://www.ncbi.nlm.nih.gov/pubmed/33809981
http://dx.doi.org/10.3390/cancers13061443

Ejemplares similares